Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “T-dxd Resistant HER2-Positive”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Ended earlyNCT03248492
What this trial is testing

DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Who this might be right for
Breast Cancer
Daiichi Sankyo 253
Testing effectiveness (Phase 2)Looking for participantsNCT06610825
What this trial is testing

Castrate Resistant Prostate Cancer Enhertu Therapy

Who this might be right for
Prostate Cancer MetastaticProstate CancerCRPC
Washington D.C. Veterans Affairs Medical Center 60
Not applicableLooking for participantsNCT07073755
What this trial is testing

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

Who this might be right for
Metastatic Breast CancerDrug ResistanceHormone Receptor-Positive Breast Cancer+3 more
Hunan Cancer Hospital 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07785856
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer

Who this might be right for
T-dxd Resistant HER2-PositiveHER2 Low Metastatic Breast Cancer
The Methodist Hospital Research Institute 27